Prognostic value of programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma

Background To investigate the expression of PD-L1(programmed death-ligand 1)in patients with esophageal squamous cell carcinoma (ESCC) and its clinical significance. Methods The tissue expression of PD-L1 protein in 139 cases of ESCC and 50 adjacent non-malignant epithelial tissues (> 5 cm from the tumor resection margins) were identified by immunohistochemical staining. Subsequently, the relationship between expression and the observed clinical characteristics was analyzed. Results The positive expression rate of PD-L1 protein was increased in tumor tissues compared to that of adjacent noncancerous mucosa tissues (40.3% vs. 22.0%, P < 0.05). The findings also indicated that PD-L1 protein expression had no significant correlation with age, gender, tumor location, differentiation and lymph node (N) status (P > 0.05). The 91 months follow-up Kaplan-Meier survival analysis showed that patients in positively expressed PD-L1 group experienced a lower survival rate compared to their negatively expressed PD-L1 counterparts (32.1% vs. 48.2%, P < 0.05). The COX regression analysis results suggested that PD-L1 represented an independent prognosis factor for ESCC. Conclusions The findings indicated that PD-L1 plays an important role in the progression of ESCC and might represent a potential therapeutic and prognostic target for ESCC patients.

[1]  J. Bergh,et al.  Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data , 2019, Clinical Cancer Research.

[2]  W. Guo,et al.  PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. , 2019, Human pathology.

[3]  J. Shang,et al.  High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy , 2018, Oncology letters.

[4]  Duck-Woo Kim,et al.  Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis , 2018, Cancer science.

[5]  Hongwei Zhang,et al.  PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma , 2018, Journal of Cancer.

[6]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[7]  Y. Doki,et al.  MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. , 2017, Oncology letters.

[8]  Haitao Ma,et al.  PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[9]  Ping Wang,et al.  Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor , 2017, Cancer science.

[10]  E. Oki,et al.  PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma. , 2017 .

[11]  S. Motoyama,et al.  PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. , 2017, Anticancer research.

[12]  Jianming Xu,et al.  Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma , 2017, Oncotarget.

[13]  Yingyong Hou,et al.  Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma , 2016, Oncotarget.

[14]  Minghui Zhang,et al.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients , 2016, Scientific Reports.

[15]  C. Kang,et al.  Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma , 2016, World journal of gastroenterology.

[16]  K. Mimori,et al.  Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome , 2016, Annals of Surgical Oncology.

[17]  S. Nomura,et al.  Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma , 2016, Oncotarget.

[18]  Guosheng Feng,et al.  Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[19]  Chengming Sun,et al.  The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis , 2015, OncoTargets and therapy.

[20]  Jie He,et al.  Annual report on status of cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[21]  Lieping Chen,et al.  Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation , 2014, Cancer journal.

[22]  W. Mao,et al.  Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? , 2012, World Journal of Surgical Oncology.

[23]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[24]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[25]  Sin-Ho Jung,et al.  Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. , 2016, European journal of cancer.

[26]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[28]  M. Lefranc,et al.  The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. , 2009, Molecular immunology.

[29]  J R Siewert,et al.  Esophageal Carcinoma , 2000, Recent Results in Cancer Research.